HB 3057
AN ACT relating to network standards for Chimeric Antigen Receptor T-Cell
89th Regular Session
Jan 14, 2025 - Jun 2, 2025 • Session ended
Awaiting Committee Assignment
Bill filed, pending referral to House committee
Committee
Not yet assigned
Fiscal Note
Not available
What This Bill Does
Requires health insurance providers in Texas to contract with and cover Chimeric Antigen Receptor T-Cell (CAR T) therapy at any certified healthcare facility that meets FDA safety and training standards. The legislation applies to various types of health benefit plans, including individual, group, and self-funded plans, and aims to expand patient access to this specialized cancer treatment. Starting January 1, 2025, health insurers cannot refuse to contract with or deny coverage for CAR T therapy at qualified treatment centers.
Subject Areas
Bill Text
relating to network standards for Chimeric Antigen Receptor T-Cell BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: SECTION 1. Title 8, Subtitle E, Insurance Code, is amended to create Chapter 1381 as follows: TITLE 8. HEALTH INSURANCE AND OTHER HEALTH COVERAGES SUBTITLE E. BENEFITS PAYABLE UNDER HEALTH COVERAGES CHAPTER 1381. NETWORK STANDARDS FOR CAR T THERAPY Sec. 1381.001. PURPOSE. The purpose of this Chapter is to expand access to Chimeric Antigen Receptor T-Cell (CAR T) therapy by allowing the cancer treatment, if covered by a health benefit plan, to be provided in any CAR T treatment center that qualifies as a certified healthcare facility in accordance with the Food and Drug Administration label governing safety certification, staff training, adverse event management, patient monitoring, and data Sec. 1381.002. APPLICABILITY OF CHAPTER. (a) This chapter applies only to a health benefit plan that provides benefits for medical or surgical expenses incurred as a result of a health condition, accident, or sickness, including an individual, group, blanket, or franchise insurance policy or insurance agreement, a group hospital service contract, or an individual or group evidence of coverage or similar coverage document that is offered by: (2) a group hospital service corporation operating under (3) a health maintenance organization operating under (4) an approved nonprofit health corporation that holds a certificate of authority under Chapter 844; (5) a multiple employer welfare arrangement that holds a certificate of authority under Chapter 846; (6) a stipulated premium company operating under Chapter (7) a fraternal benefit society operating under Chapter (8) a Lloyd's plan operating under Chapter 941; or (9) an exchange operating under Chapter 942. (b) Notwithstanding any other law, this chapter applies to: (1) a small employer health benefit plan subject to Chapter 1501, including coverage provided through a health group cooperative under Subchapter B of that chapter; (2) a standard health benefit plan issued under Chapter (3) a basic coverage plan under Chapter 1551; (4) a basic plan under Chapter 1575; (5) a primary care coverage plan under Chapter 1579; (6) a plan providing basic coverage under Chapter 1601; and (7) a self-funded health benefit plan sponsored by a professional employer organization under Chapter 91, Labor Code. Sec. 1381.003. NETWORK STANDARDS. (a) No health benefit plan in the state that provides coverage for Chimeric Antigen Receptor T-Cell (CAR T) therapy may refuse to contract for the administration of any CAR T therapy by any provider that qualifies as a certified healthcare facility in accordance with approved procedure under the CAR-T product license by the FDA. (b) No health benefit plan in the state that covers CAR T therapy may deny coverage for the administration of any CAR T therapy by any provider that qualifies as a certified healthcare facility in accordance with approved procedure under the CAR-T (c) This section shall apply to any health benefit plan that is delivered, issued for delivery, or renewed on or after January 1, Sec. 1381.003. RULES. The commissioner shall adopt rules as necessary to administer this chapter. SECTION 2. This Act takes effect September 1, 2025.
Bill History
Bill filed: AN ACT relating to network standards for Chimeric Antigen Receptor T-Cell
Related Guides
Learn more about tracking Texas legislation and working with lobbyists.
How to Read & Track Texas Bills
Master bill numbering, understand legislative language, and learn effective tracking strategies.
Understanding Texas Legislative Deadlines
Navigate the 140-day session with critical calendar dates and filing deadlines.
How Laws Get Made in Texas
Follow a bill's journey from filing to the governor's desk through committees and floor votes.
When Should Your Business Hire a Lobbyist?
Discover the signs that your business needs professional advocacy at the Texas Capitol.